Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Top Cited Papers
- 1 November 2007
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 8 (11), 1018-1029
- https://doi.org/10.1016/s1470-2045(07)70342-x
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylateBlood, 2006
- Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to ImatinibMolecular and Cellular Biology, 2006
- Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatmentCancer Genetics and Cytogenetics, 2005
- Drug resistance in cancer: Principles of emergence and preventionProceedings of the National Academy of Sciences, 2005
- Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and womenPharmacogenetics, 2003
- Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cellsCancer Science, 2003
- Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyBlood, 2003
- Mutations in the ABL kinase domain pre-exist the onset of imatinib treatmentSeminars in Hematology, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001